Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study)

Diabetic kidney disease (DKD) is a devastating complication that affects an estimated third of patients with type 1 diabetes mellitus (DM). There is no cure once the disease is diagnosed, but early treatment at a sub-clinical stage can prevent or at least halt the progression. DKD is clinically diagnosed as abnormally high urinary albumin excretion rate (AER). We hypothesize that subtle changes in the urine metabolome precede the clinically significant rise in AER. To test this, 52 type 1 diabetic patients were recruited by the FinnDiane study that had normal AER (normoalbuminuric). After an average of 5.5 years of follow-up half of the subjects (26) progressed from normal AER to microalbuminuria or DKD (macroalbuminuria), the other half remained normoalbuminuric. The objective of this study is to discover urinary biomarkers that differentiate the progressive form of albuminuria from non-progressive form of albuminuria in humans. Metabolite profiles of baseline 24 h urine samples were obtained by gas chromatography–mass spectrometry (GC–MS) and liquid chromatography–mass spectrometry (LC–MS) to detect potential early indicators of pathological changes. Multivariate logistic regression modeling of the metabolomics data resulted in a profile of metabolites that separated those patients that progressed from normoalbuminuric AER to microalbuminuric AER from those patients that maintained normoalbuminuric AER with an accuracy of 75% and a precision of 73%. As this data and samples are from an actual patient population and as such, gathered within a less controlled environment it is striking to see that within this profile a number of metabolites (identified as early indicators) have been associated with DKD already in literature, but also that new candidate biomarkers were found. The discriminating metabolites included acyl-carnitines, acyl-glycines and metabolites related to tryptophan metabolism. We found candidate biomarkers that were univariately significant different. This study demonstrates the potential of multivariate data analysis and metabolomics in the field of diabetic complications, and suggests several metabolic pathways relevant for further biological studies.

[1]  P. Kimmelstiel,et al.  Benign and Malignant Hypertension and Nephrosclerosis: A Clinical and Pathological Study. , 1936, The American journal of pathology.

[2]  J. Mrochek,et al.  Identification and biochemical significance of substituted furans in human urine. , 1972, Clinical chemistry.

[3]  R. Chalmers,et al.  Urinary organic acids in man. I. Normal patterns. , 1976, Clinical chemistry.

[4]  Graham K. Rand,et al.  Quantitative Applications in the Social Sciences , 1983 .

[5]  R. Chalmers,et al.  Urinary Excretion of l-Carnitine and Acylcarnitines by Patients with Disorders of Organic Acid Metabolism: Evidence for Secondary Insufficiency of l-Carnitine , 1984, Pediatric Research.

[6]  W. Guder,et al.  Carnitine metabolism in isolated rat kidney cortex tubules. , 1986, Biological chemistry Hoppe-Seyler.

[7]  J. Baynes,et al.  Detection of 3-deoxyfructose and 3-deoxyglucosone in human urine and plasma: evidence for intermediate stages of the Maillard reaction in vivo. , 1992, Archives of biochemistry and biophysics.

[8]  G. Lou,et al.  Kynurenic acid distribution into brain and peripheral tissues of mice. , 1994, Canadian journal of physiology and pharmacology.

[9]  C. Rebouche,et al.  Carnitine metabolism and its regulation in microorganisms and mammals. , 1998, Annual review of nutrition.

[10]  C. Heizmann,et al.  Evaluation of urinary acylglycines by electrospray tandem mass spectrometry in mitochondrial energy metabolism defects and organic acidurias. , 2000, Molecular genetics and metabolism.

[11]  Matthew D. Davis,et al.  Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. , 2000, The New England journal of medicine.

[12]  Trevor Hastie,et al.  The Elements of Statistical Learning , 2001 .

[13]  Y. Akagi,et al.  Effect of galactose diet removal on the progression of retinal vessel changes in galactose-fed dogs. , 2002, Investigative ophthalmology & visual science.

[14]  D. Pawlak,et al.  Tryptophan Metabolism via the Kynurenine Pathway in Experimental Chronic Renal Failure , 2002, Nephron.

[15]  N. Chaturvedi,et al.  Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. , 2004, Diabetes care.

[16]  A. O. Mohamed,et al.  Incidence of end-stage renal disease in madina munawarah. , 2004, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[17]  D. Chan,et al.  Cancer Proteomics: In Pursuit of “True” Biomarker Discovery , 2005, Cancer Epidemiology Biomarkers & Prevention.

[18]  David W. Johnson.  Contemporary clinical usage of LC/MS: analysis of biologically important carboxylic acids. , 2005, Clinical biochemistry.

[19]  J. Gross,et al.  Diabetic nephropathy: diagnosis, prevention, and treatment. , 2005, Diabetes care.

[20]  J. Miller,et al.  Statistics and chemometrics for analytical chemistry , 2005 .

[21]  A. Reunanen,et al.  Incidence of end-stage renal disease in patients with type 1 diabetes. , 2005, JAMA.

[22]  L. Vernez.  Analysis of carnitine and acylcaritines in biological fluids and application to a clinical study , 2005 .

[23]  M. Mauer,et al.  Enhancing the predictive value of urinary albumin for diabetic nephropathy. , 2006, Journal of the American Society of Nephrology : JASN.

[24]  K. Kaski,et al.  Diagnosing diabetic nephropathy by 1H NMR metabonomics of serum , 2007, Magnetic Resonance Materials in Physics, Biology and Medicine.

[25]  A. Smilde,et al.  Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. , 2006, Analytical chemistry.

[26]  T. Hankemeier,et al.  Microbial metabolomics with gas chromatography/mass spectrometry. , 2006, Analytical chemistry.

[27]  Erik J. Saude,et al.  Variation of metabolites in normal human urine , 2007, Metabolomics.

[28]  R. Bischoff,et al.  Comparative urine analysis by liquid chromatography-mass spectrometry and multivariate statistics: method development, evaluation, and application to proteinuria. , 2007, Journal of proteome research.

[29]  K. Kaski,et al.  1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death , 2008, Molecular systems biology.

[30]  Guanghui Hu,et al.  Multivariate classification analysis of metabolomic data for candidate biomarker discovery in type 2 diabetes mellitus , 2008, Metabolomics.

[31]  Age K. Smilde,et al.  Discriminant Q2 (DQ2) for improved discrimination in PLSDA models , 2008, Metabolomics.

[32]  K. Kaski,et al.  Metabolic Phenotypes, Vascular Complications, and Premature Deaths in a Population of 4,197 Patients With Type 1 Diabetes , 2008, Diabetes.

[33]  A. Jankevics,et al.  Metabolomic studies of experimental diabetic urine samples by 1H NMR spectroscopy and LC/MS method , 2009 .

[34]  W. R. Wikoff,et al.  Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites , 2009, Proceedings of the National Academy of Sciences.

[35]  Frans M van der Kloet,et al.  Analytical error reduction using single point calibration for accurate and precise metabolomic phenotyping. , 2009, Journal of proteome research.

[36]  Merlin C. Thomas,et al.  The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes , 2009, Diabetes.

[37]  Xiaomei Yan,et al.  Metabonomics research of diabetic nephropathy and type 2 diabetes mellitus based on UPLC-oaTOF-MS system. , 2009, Analytica chimica acta.

[38]  Guy Lapalme,et al.  A systematic analysis of performance measures for classification tasks , 2009, Inf. Process. Manag..

[39]  Merlin C. Thomas,et al.  Blood Pressure Lowering for the Prevention and Treatment of Diabetic Kidney Disease , 2012, Drugs.